Barbara Pereira Mello

Barbara Pereira Mello

Auto-generated profile, based on publicly available information

Barbara Pereira Mello

Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, USA

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2020 in Journal of Investigative Dermatology
Verified
Journal Article
Closed access
DHDaniele Seo Hieda
Daniele Seo Hieda
LCLarissa Anastacio da Costa Carvalho
Larissa Anastacio da Costa Carvalho
BMBarbara Vaz de Mello
Barbara Vaz de Mello
EOErica Aparecida de Oliveira
Erica Aparecida de Oliveira
SASilvia Romano de Assis
Silvia Romano de Assis
SBSilvia Berlanga de Moraes Barros
Silvia Berlanga de Moraes Barros

26 May 2025 in Nature Communications
Verified
Journal Article
Open access
PDF file
KKKenta Kawasaki
Kenta Kawasaki
SSSohrab Salehi
Sohrab Salehi
YZYingqian A. Zhan
Yingqian A. Zhan
KCKevin Chen
Kevin Chen
JLJun Ho Lee
Jun Ho Lee
CRCharles M. Rudin
Charles M. Rudin
Small cell lung cancer (SCLC) is known for its high metastatic potential, with most patients demonstrating clinically evident metastases in multiple organs at diagnosis. The factors contributing to this exceptional metastatic capacity have not been defined. To bridge this gap, we compare gene expression in SCLC patient samples who never experienced metastasis or relapse throughout their clinical course, versus primary SCLC patient samples from more typical patients who had metastatic disease at diagnosis. This analysis identifies FOXA2 as a transcription factor strongly associated with SCLC metastasis. Subsequent analyses in experimental models demonstrates that FOXA2 induces a fetal neuroendocrine gene expression program and promotes multi-site metastasis. Moreover, we identify ASCL1, a transcription factor known for its initiating role in SCLC tumorigenesis, as a direct binder of the FOXA2 promoter and regulator of FOXA2 expression. Taken together, these data define the ASCL1-FOXA2 axis as a critical driver of multiorgan SCLC metastasis.

20 July 2026 in Translational Oncology
Verified
Journal Article
Open access
ECEmily A. Costa
Emily A. Costa
BMBarbara Pereira Mello
Barbara Pereira Mello
CWCorrin Wohlhieter
Corrin Wohlhieter
SNSubhiksha Nandakumar
Subhiksha Nandakumar
STSamuel Tischfield
Samuel Tischfield
CRCharles M. Rudin
Charles M. Rudin